ACADIA Pharma (ACAD) - Price to Earnings Ratio
The current P/E ratio for ACADIA Pharmaceuticals (ACAD) demonstrates a consolidation phase, where the parameter value reaches 8.80. This trend is supported by patent exclusivity, which protects yields from generics. Stability is ensured by a strong team of neurobiologists incentivized by long-term options. The cash flow is based on the sale of Parkinson's disease treatments through insurance funds and Medicare government programs.
Comprehensive metric breakdowns and analytics for ACADIA Pharmaceuticals Inc (ACAD)
- price and consensus price forecast:
- market capitalization indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Capital Coefficient ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital|Short-Term Debt to Capital ACADIA Corp|ACAD - Company Total Debt|Debt to Net Assets Ratio ACADIA Pharmaceuticals Inc.|ACAD - Company Long-Term Debt|Current Liabilities ACADIA Pharmaceuticals|Intermediate Coverage Ratio acadia-pharm.com
- net income and valuation ratios data:
ACAD - Net Profit|Projected Future Earnings ACADIA Pharmaceuticals|ACAD - Price to Earnings Ratio|Future Price to Earnings Multiple ACADIA Pharma|ACAD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio ACADIA Pharmaceuticals Inc.|ACAD - Operating profit EBITDA|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months acadia-pharm.com|ACAD - Earnings growth in current year|Expected net earnings per share growth next year ACADIA Pharmaceuticals
General company analysis:acadia-pharm.com - ACAD
For ACADIA Pharmaceuticals (ACAD), this ratio reflects the market value of the business relative to its net income, allowing for an assessment of the asset's premium. By analyzing the company's P/E ratio, an investor can compare current capitalization with financial resilience regarding Nuplazid patent disputes and Daybue costs, identifying either an undervalued asset or the risk of inflated expectations amid operating expenses.
Analysis of competing companies
P/E Multiple biogen.com|P/E Multiple NBIX|Price to Earnings Ratio Regencell Bioscience Ltd RGC|P/E Multiple AXSM (Axsome Therapeutics Inc)|P/E Multiple Xenon Corp XENE|Viking Therapeutics - P/E Multiple|SUPN (supernus.com) - Price to Earnings Multiple|CPRX: P/E Multiple|DNLI - Business Payback Period|HRMY (Harmony Pharma) - P/E Multiple|P/E Multiple Biohaven Corp|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Company Value to Net Income|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|AVXL (Anavex) - Market Cap to Net Income|CeriBell Corp - P/E Multiple|Company Value to Net Income PRTA (Prothena Corporation)|ALEC: P/E Multiple|annexonbio.com (ANNX) - P/E Multiple|Price to Earnings Ratio Omeros Corp|NGNE: Company Value to Net Income|Price to Earnings Ratio AC Immune Corp (ACIU)|Price to Earnings Ratio Voyager Corp VYGR|P/E Multiple NMRA (Neumora Therapeutics)|P/E Multiple scilexholding.com SCLX|Tevogen Bio - P/E Multiple|Alpha Cognition (ACOG) - Price to Earnings Ratio|CGTX: P/E Multiple|Market Cap to Earnings Inhibikase Pharma (IKT)|Price to Earnings Ratio SAVA|P/E Multiple Assertio Therapeutics|Price to Earnings Ratio COYA (Coya Therapeutics, Inc.)|Market Price to Net Income Ratio VTGN|P/E Multiple OVID (Ovid Therapeutics)|Business Payback Period Acumen Pharmaceuticals, Inc (ABOS)|CervoMed Inc. - P/E Multiple|Alterity Therapeutics (ATHE) - Price to Earnings Ratio|CLNN: P/E Multiple|PepGen (PEPG) - P/E Multiple|Price to Earnings Ratio Jupiter Neurosciences|Price to Earnings Ratio RLMD|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|Business Payback Period gracetx.com|P/E Multiple AIFF (Firefly Neuroscience)|P/E Multiple ANEW Medical KLTO|NeuroSense Therapeutics, Ltd. - P/E Multiple|Reviva Pharmaceuticals, Inc. (RVPH) - Price to Earnings Ratio|MTVA: P/E Multiple|neuraxis.com (NRXS) - P/E Multiple|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Price to Earnings Multiple PASG (Passage Bio Corp)|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|Minerva - Price to Earnings Multiple|P/E Multiple ATHA (Athira Pharma, Inc.)|addextherapeutics.com (ADXN) - Market Cap to Earnings|ALZN: Price to Earnings Ratio|CYCN - P/E Multiple|protagenic.com (PTIX) - Price to Earnings Ratio|Pasithea Therapeutics Corp. - Company Value to Net Income|Price to Earnings Ratio Cortigent Inc|Market Cap to Earnings avenuetx.com ATXI|P/E Multiple BCLI|P/E Multiple Cara Therapeutics Inc. (CARA)|P/E Multiple CHRO (Chromocell Therapeutics Corporation)|ELYM - Price to Earnings Ratio|Intra-Cellular - P/E Multiple|LBPH - P/E Multiple|MRNS: P/E Multiple|Price to Earnings Multiple NKGN|NRBO (NeuroBo) - P/E Multiple|Sage Therapeutics Inc (SAGE) - Business Payback Period|P/E Multiple SNPX|P/E Multiple trevena.com (TRVN)|Vigil Neuroscience, Inc. - Price to Earnings Ratio|Company Value to Net Income WENA|CERE - Price to Earnings Ratio
